Bank of Montreal
GLUE icon

Bank of Montreal’s Monte Rosa Therapeutics GLUE Stock Holding History

Bank of Montreal’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,379
Closed -$99.2K – 3976
2023
Q2 		$99.2K Buy
+11,379
New +$73.6K ﹤0.01% 3448

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of Montreal's GLUE Position: Q3 2023 in Review

Bank of Montreal sold out of Monte Rosa Therapeutics (GLUE) in Q3 2023, closing a stake of 11,379 shares — an estimated $99.2K sold.

Bank of Montreal first reported a position in GLUE in Q2 2023 and held it in 1 quarter. The position peaked at $99.2K in Q2 2023. 71 funds tracked by Wall St. Rank hold GLUE as of Q3 2023.

  • Bank of Montreal reported no remaining Monte Rosa Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Bank of Montreal sold 11,379 Monte Rosa Therapeutics shares in Q3 2023, an estimated $99.2K.
  • Bank of Montreal first reported a position in Monte Rosa Therapeutics in Q2 2023 and held it in 1 quarter.
  • Bank of Montreal's Monte Rosa Therapeutics position peaked at $99.2K in Q2 2023.
  • 71 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2023.

Based on Bank of Montreal's 13F filing for Q3 2023, filed 1 Nov 2023.